SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

IBRXs high-volume rally is drawing attention ahead of founder Patrick Soon-Shiongs scheduled Piper Sandler fireside chat, where traders are looking for clinical-trial updates. Bulls point to a possible breakout and short-covering, while partnership and NIH cancer-vaccine links remain speculation and some traders caution that the move lacks a new company disclosure.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorillas proposed first U.S. data-center acquisition and plan to build a larger AI-infrastructure portfolio are drawing attention. Traders are split: some view the expansion as a growth opportunity, while many question how it will be financed and whether the company can execute, citing dilution concerns and skepticism over earlier promises.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Goldman Sachs upgrade to Buy, citing Palantirs opportunities in sovereign AI and customized software, is helping drive attention alongside a breakout to fresh highs. Bulls are celebrating the momentum and speculating about short covering, while skeptics warn the valuation is stretched and the rally could reverse.

Datadog, Inc. engages in the development of a monitoring and analytics platform for developers, information technology operations teams and business users. Its platform integrates and automates infrastructure monitoring, application performance monitoring and log management to provide real-time observability of its customers' entire technology stack. The company was founded by Olivier Pomel and Alexis Lê-Quôc on June 4, 2010 and is headquartered in New York, NY.

Datadog Inc - Ordinary Shares - Class A

Datadog Inc

Datadog is drawing attention as it rallies with strength across software stocks and traders point to a breakout toward record highs. Bulls cite momentum and demand for cloud monitoring and AI observability, while skeptics question its rich valuation and warn the advance could reverse.

T-Mobile US, Inc. engages in the provision of wireless communications services under the T-Mobile and MetroPCS brands. It offers postpaid and prepaid wireless voice, messaging and data services, and wholesale wireless services. The company was founded in 1994 and is headquartered in Bellevue, WA.

T-Mobile US Inc

SpaceXs spectrum acquisition and Starlink Mobile ambitions have triggered a sharp selloff in T-Mobile shares as traders weigh the prospect of a new wireless competitor. The community is split between viewing the threat as a long-term risk to carriers and calling the reaction an overreaction given SpaceXs need to build out its network.

Shopify, Inc. is a global commerce company that provides essential internet infrastructure for commerce, offering trusted tools to start, scale, market, and run a retail business of any size. The Company's software enables merchants to run their business across all of their sales channels, including web and mobile storefronts, physical retail locations, social media storefronts and marketplaces. The Shopify platform provides merchants with a single view of their business across all of their sales channels and enables them to manage products and inventory, process orders and payments, fulfill and ship orders, build customer relationships, source products, leverage analytics and reporting and access financing, all from one integrated back office. The company was founded on September 28, 2004 and is headquartered in Ottawa, Canada.

Shopify Inc - Ordinary Shares - Class A (Sub Voting)

Shopify Inc

Shopifys rally is drawing attention as traders focus on its Meta Muse integration, which lets the AI agent route purchases through Shopify merchants Shop Pay checkout, and on bullish analyst views of agentic commerce as a potential growth channel. Traders are celebrating the momentum, while others caution that monetization may take time and watch for a pullback near resistance.

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Starknet

STRK is drawing attention amid a volume-backed rally and optimism around Starknets privacy and Bitcoin DeFi initiatives, including strkBTC and STRK20, alongside its post-quantum security narrative. Traders are bullish on the technology and momentum, while others warn that token unlocks and the sharp move could keep selling pressure or make the rally short-lived.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

Repeated analyst price-target cuts and valuation concerns are dominating discussion around APPs sharp pullback ahead of its upcoming earnings report. Long-term bulls point to the companys ad growth, cash flow and e-commerce opportunity, while many holders are frustrated by the volatile price action and debate whether the selloff reflects deteriorating prospects or an opportunity.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Attention is focused on the wet-AMD durability race: Kodiaks positive late-stage Zenkuda data have prompted traders to reassess AXPAXLIs competitive position and contributed to concern about Oculars recent share-price weakness. The community is debating whether SOL-1s results and potential longer dosing intervals can distinguish AXPAXLI; many are looking to SOL-R and the planned NDA filing for further clarity.

Intellia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

A Barclays downgrade and reported low price target have sparked debate, with bears citing competition and adoption risks while bulls argue Intellias one-time HAE gene therapy, lonvo-z, could offer a differentiated treatment. Traders are also watching for further clinical data, but the anticipated conference updates remain speculative.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Huge Narratives and Market Moments

The Market is once again producing the kind of outsized news that can quickly turn obscure names into market-watchlist favorites. Kraig Biocraft Laboratories (OTCQB:KBLB), HCW Biologics (NASDAQ:HCWB), Uxin (NASDAQ:UXIN), Green Circle Decarbonize Technology (NYSEAMERICAN:GCDT), Powell Max Limited (NASDAQ: PMAX), Netcapital (NASDAQ:NCPL), STAK Inc. (NASDAQ:STAK), and Wetour Robotics (NASDAQ:WETO) are each tied to different narratives.

HCW Biologics Commences 1-for-6 Reverse Stock Split

(RTTNews) - HCW Biologics Inc. (HCWB), a clinical-stage biopharmaceutical company, Friday announced that it has been approved for a 1-for-6 reverse stock split of the company's common stock, with par value of $0.0001, effective June 30...

Microcap HCW Biologics' Therapy Shows Early Promise Against Autoimmune Hair Loss

HCW Biologics reports positive Phase 1 data for HCW9302, with all 2nd-cohort alopecia patients showing a clinical response.read more...

Why Is HCW Biologics Stock Surging On Friday?

HCW Biologics Inc. (NASDAQ: HCWB) stock rallies on Friday as a $4 million private placement offering boosts liquidity for its clinical trials.read more...

This Emerging Biotech Wave Could Create the Next Monster Healthcare Winners

The biotechnology sector continues attracting speculative capital as investors aggressively position around next-generation oncology, metabolic disease, and CNS therapy platforms. Artificial intelligence, precision medicine, RNA biology, and novel drug delivery technologies are rapidly reshaping how Wall Street evaluates emerging healthcare companies. As larger pharmaceutical companies race to secure pipeline assets and differentiated platforms, smaller clinical-stage companies with compelling preclinical or clinical data are increasingly finding themselves under the spotlight. $AKTX, $NTHI, $MTVA, $HCWB, $BAC, $STT, $BCS

Why HCW Biologics Stock Is Surging On Thursday?

HCW Biologics Inc. (NASDAQ:HCWB) stock is rallying after securing a $4 million private placement to fund its clinical pipeline. Read the full market breakdown.read more...

Biotech and Biologics Break Out: These Tiny Stocks Are Suddenly Dominating the Market Conversation

Emerging biotech and biologics names exploded onto traders’ radar Wednesday as a wave of clinical milestones, regulatory momentum, strategic acquisitions, and high-volume technical breakouts fueled aggressive speculation across the sector. $HCWB, $TGNT, $KBLB, $SLS, $RKDA, $ROIV, $SLXN

Why HCW Biologics Stock Is Falling On Tuesday?

HCW Biologics Inc. (NASDAQ: HCWB) stock falls on Tuesday. Retail traders lock in gains after a 262% surge driven by Q1 earnings and pipeline updates.read more...

What's Going On With HCW Biologics Stock Monday?

HCW Biologics (HCWB) reports Q1 EPS of $0.37 and $6.54M in sales. Find out why the stock skyrocketed and what's next.read more...

Clinical-Stage Biopharma Surges on Profit Swing and Imminent Phase 1 Data Readout

The market for autoimmune disease therapies is being reshaped by a new generation of biologics targeting regulatory T cells, the immune system's own braking mechanism. Alopecia areata, an autoimmune disorder that causes patchy or complete hair loss, affects millions worldwide and has only recently received its first FDA-approved oral therapies, each carrying significant tolerability concerns. Developers chasing safer, more selective alternatives have made Treg-expanding approaches one of the most closely watched corners of clinical-stage immunology.Shares of HCW Biologics Inc. (Nasdaq: ...

• Reported GAAP EPS of -$11.58 up 71.58% YoY
• Reported revenue of $0.14M up 1969.74% YoY

HCW Biologics faces substantial going concern risks, significantly increased quarterly net losses, and operational difficulties in manufacturing reagents for the CAR-T therapy market that may impede future business growth.

HCW Biologics demonstrated preliminary clinical efficacy for its lead autoimmune candidate, re-acquired commercial-ready reagent rights to support future partnerships, and remains on track for upcoming T-cell engager clinical trials.

HCW Biologics Inc. is a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation, and age-related diseases. The firm considers age-related low-grade chronic inflammation as a contributing factor to several chronic diseases and conditions, such as cancer, cardiovascular disease, diabetes, neurodegenerative diseases, and autoimmune diseases. The company was founded by Hing C. Wong on April 2, 2018 and is headquartered in Miramar, FL.

HCW Biologics Inc

HCWB Stock Soars Pre-Market On Positive Research Results For CAR-T Cell Therapy

Equity

Neutral Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$1.60
Prev Close	$1.53
Open	$1.60
Dividend Yield	0.00%
50-Day Moving Average	$2.46
Beta	0.50
Avg. Volume	918,103.63
PE Ratio	-0.06

52-Week High	$27.30
52-Week Low	$1.50
Market Capitalization	$3.42M
EPS (Annual)	-$63.78
Price to Book	0.35
Revenue Per Employee	$1,549.49

Feed

News

Sentiment

Earnings

Fundamentals

Info

HCWB Fundamentals